vTv Therapeutics Inc.

Equities

VTVT

US9183852048

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 24/05/2024 BST			5-day change	1st Jan Change
27.72 ^USD	-4.08%		-1.74%	+141.04%

05-09	VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	VTv Therapeutics Inc. Announces Board Changes	CI

VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 12, 2022 at 11:05 am

vTv Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 2 million compared to USD 0.987 million a year ago. Net loss was USD 7.01 million compared to USD 4.24 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.08 a year ago.

Latest news about vTv Therapeutics Inc.

VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
VTv Therapeutics Inc. Announces Board Changes	03-14	CI
VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
VTv Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-13	CI
VTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes	03-04	CI
Top Midday Gainers	02-28	MT
VTv Therapeutics Inc. Announces Board Changes	02-28	CI
VTv Therapeutics Inc. announced that it has received $50.961457 million in funding from JDRF T1D Fund, Samsara BioCapital LLC and another investors	02-26	CI
Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors	12-22	CI
VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer	11-02	CI
North American Morning Briefing : China Trouble -2-	18/08/23	DJ
VTv Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
VTv Therapeutics Says Cantex Pharmaceuticals Received IP License for Azeliragon	16/06/23	MT
Cantex Pharmaceuticals Receives US Patent Covering vTv Therapeutics' Azeliragon	24/05/23	MT
VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Earnings Flash (VTVT) VTV THERAPEUTICS Reports Q4 Revenue $9,000	06/03/23	MT
VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	06/03/23	CI
VTv Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	06/03/23	CI
VTv Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	05/03/23	CI
VTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel	01/02/23	CI
VTv Therapeutics Names Steven Tuch Finance Chief	13/12/22	MT
VTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer	13/12/22	CI
VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Northland Securities Raises Price Target on vTv Therapeutics to $2 From $1.50, Maintains Outperform Rating	18/08/22	MT

Chart vTv Therapeutics Inc.

Duration

Period

More charts

Company Profile

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

Sector

Biotechnology & Medical Research

Calendar

11/06/2024 - Annual General Meeting

More about the company

	1st Jan change	Capi.
VTV THERAPEUTICS INC.	+141.04%	67.44M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-0.29%	22.1B
GENMAB A/S	-9.28%	18.34B
WUXI APPTEC CO., LTD.	-41.70%	16.59B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs